Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3861943 | 0.94 | ALDH1A1 (0.60) | ALDH1A1HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL27813833 | 0.90 | HRH3 (0.61) | ALDH1A1HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL1507268 | 0.89 | HRH3 (0.52) | ALDH1A1HRH3KCNH2 | |
| SCHEMBL599173 | 0.89 | HRH3 (0.52) | ALDH1A1HRH3KCNH2 | |
| SCHEMBL1507140 | 0.89 | HRH3 (0.52) | ALDH1A1HRH3KCNH2 | |
| SCHEMBL1507226 | 0.89 | HRH3 (0.52) | ALDH1A1HRH3KCNH2 | |
| SCHEMBL27739891 | 0.88 | HRH3 (0.64) | ALDH1A1HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL1507265 | 0.87 | HRH3 (0.53) | ALDH1A1HRH3KCNH2 | |
| SCHEMBL16207888 | 0.87 | HRH3 (0.48) | ALDH1A1HRH3KCNH2POLBHSD17B10 | |
| SCHEMBL1507054 | 0.86 | HRH3 (0.50) | ALDH1A1HRH3KCNH2L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | ALDH1A1 502/4885HRH3 1322/4885KCNH2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.